The Atrial Fibrillation Network association (AFNET) is an interdisciplinary research network comprising scientists and physicians from universities, hospitals and practices dedicated to improving the management of atrial fibrillation through coordinated research in Germany and Europe.

Its main objective is to conduct high quality investigator-initiated clinical trials and registries on a national and international level. Clinical trial results are the major link between basic science and medical care.

The AFNET structure faciliates dissemination of scientific results to relevant target groups representing all levels of care of atrial fibrillation management. Due to its long lasting experience, AFNET is a highly accepted specialist in cardiovascular clinical research.

The AFNET association continues the long-term activities of the network which has been funded by the German Federal Ministry of Research and Education over a decade until 2014.

As a joint initiative AFNET and European Heart Rhythm Association (EHRA) organise AFNET/EHRA consensus conferences every two years. These expert meetings focus on „hot topics“ in the research area of atrial fibrillation. Results of the conferences were published regularly and encompass recommendations for atrial fibrillation research and management. Therefore these results potentially improve atrial fibrillation management.

Doreen_Haase.pngDoreen Haase

Doreen Haase is a project manager at the Atrial Fibrillation Network (AFNET) in Münster, Germany.

She graduated in Biomedicine from Würzburg University, Germany. After completing her Dr. rer. nat. in Immunology at the Charité hospital in Berlin, Germany, she moved to Singapore for a  postdoc position in the Singapore Immunology Network (SIgN, A*STAR). There she gained experience in managing clinical trials.

In 2016 she joined the Atrial Fibrillation Network to support the CATCH ME project.






Thomas_Weiss.jpgThomas Weiss

Thomas Weiss is the Managing Director of the Atrial Fibrillation Network (Kompetenznetz Vorhofflimmern e.V.) in Münster, Germany.

He graduated in Chemistry from Ulm University, Germany and completed his Dr. rer. nat. at the Technical University of Munich, Germany.

After several years as a CEO in chemical research companies and associations he started to work in the field of clinical research as a Managing Director at the Atrial Fibrillation Network. He held this position for nine years before he accepted an employment at the University Hospital of Muenster as a Center Manager in cardiovascular medicine.  In 2016 he went back into his former position at the Atrial Fibrillation Network.